Cancer Diagnosis Program | Biorepositories and Biospecimen Research Branch

Search BRD Papers

KRAS mutational status of endoscopic biopsies matches resection specimens.

Author(s): Yang QH, Schmidt J, Soucy G, Odze R, Dejesa-Jamanila L, Arnold K, Kuslich C, Lash R

Publication: J Clin Pathol, 2012, Vol. 65, Page 604-7

PubMed ID: 22461648 PubMed Review Paper? No

Purpose of Paper

Conclusion of Paper

Studies

1. Study Purpose

   This restrospective study investigated if KRAS mutational status determined in FFPE endoscopic biopsy reflects the KRAS status in matched resection specimens from 30 patients with colorectal cancer. The authors did not provide the details of specimen acquisition and processing. Tumor areas that contained a minimum of 30% tumor nuclei and less than 30% necrosis were microdissected and placed in a tube. DNA was isolated from the resultant 60 resection specimens, 30 matched CRC biopsy specimens, and 12 biopsy specimens from the same patient that contained a distinct intramucosal component using the QIAamp DNA FFPE tissue kit. KRAS Exons 2 (including codon 12 and 13) and exon 3 (including codon 61) were amplified and sequenced bidirectionally.

   Summary of Findings:

   KRAS mutations were identified in twelve of the 30 patients (40%) with nine (75%) having mutations at codon 12 and three (25%) having mutations at codon 13. Importantly, there was 100% concordance in mutational status between matched resection and biopsy specimens. Among the twelve biopsy specimens with a distinct intramucosal component, two (16.7%) harbored an additional KRAS mutation. 

   Biospecimens

   • Tissue - Colorectal

   Preservative Types

   • Formalin

   Diagnoses:

   • Neoplastic - Carcinoma

   Platform:

   Analyte	Technology Platform
   DNA	DNA sequencing

   Pre-analytical Factors:

   Classification	Pre-analytical Factor	Value(s)
   Biospecimen Acquisition	Method of tissue acquisition	Biopsy Surgical resection

   View more